<DOC>
	<DOCNO>NCT01077427</DOCNO>
	<brief_summary>Improvement clinical outcome patient resectable pancreatic carcinoma intensify adjuvant treatment additional application cisplatin regional deep hyperthermia .</brief_summary>
	<brief_title>Hyperthermia European Adjuvant Trial</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Any ductal adenocarcinoma pancreas confirm histology 2 . Previous R0 R1 resection pancreatic tumor standardize procedure 3 . No previous concomitant treatment pancreatic carcinoma like radiation , neoadjuvant therapy immunotherapy 4 . No tumor recurrence surgery 5 . Postoperative tumor marker ( CEA/CA199 ) ≤ 2.5 x upper limit normal ( ULN ) document within 1 week prior randomization 6 . Performance status ECOG 02 7 . Adequate bone marrow function define WBC count ≥ 3.5 x 109/L platelet ≥ 150 x 109/L haemoglobin ≥ 9 g/dl document within 1 week prior randomization 8 . Adequate renal function define serum creatinine ≤ 1.2 mg/dL calculate GFR ≥ 60 mL/min document within 1 week prior randomization 9 . Adequate coagulatory function define Quickvalue ≥ 70 % aPTT ≤ 1.5 x ULN document within 1 week prior randomization 10 . Transaminases ( AST , ALT ) ≤ 3 x ULN bilirubin ≤ 2 x ULN document within 1 week prior randomization 11 . At least 18 year age 12 . Women childbearing potential fertile men must use adequate contraceptive measure least 3 month ( female ) 6 month ( male ) completion study therapy ( Adequate method woman oral contraceptive estrogen progesterone , vaginal ring , contraceptive patch , estrogenfree ovulation inhibitor , intrauterine device progesterone,3month injection depot progesterone , implant set free progesterone , abstinence sterilization ( vasectomy ) male partner . Men must use condom . ) 13 . Women childbearing potential must negative pregnancy test within 1 week prior randomization ( postmenopausal woman amenorrhea 1 year regard childbearing potential ) 14 . Written inform consent Exclusion criterion : 1 . Cystic carcinoma pancreas 2 . Periampullary , papillary cancer 3 . Metastatic disease 4 . Presence active infection grade 3 high 5 . Other severe disease could impair patient 's ability participate study accord investigator 's opinion 6 . Pregnant breastfeed woman 7 . Known allergy contraindication regard substance procedure study therapy 8 . Severe , nonhealing wound , ulcer bone fracture 9 . Participation another clinical trial study within 4 week prior randomization 10 . Past current abuse illegal legal drug alcohol 11 . Other primary malignant diseases medical history last 5 year ( exception : carcinoma situ cervix adequately treat basal cell carcinoma skin ) . 12 . Permanent cardiac pacemaker 13 . Gross adiposity define BMI &gt; 40 kg/m² 14 . Treatment regional hyperthermia possible technical reason ( e.g . metal implant )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>adjuvant treatment</keyword>
	<keyword>hyperthermia</keyword>
</DOC>